Evidence map›Paper›PMID 31846139›Full record

ReviewJournal of magnetic resonance imaging : JMRI2020

Current state of the art MRI for the longitudinal assessment of cystic fibrosis.

Jason C Woods, Jim M Wild, Mark O Wielpütz, John P Clancy, Hiroto Hatabu, Hans-Ulrich Kauczor, Edwin J R van Beek, Talissa A Altes

Open access · greenAbstract readReview
In one paragraph

Review in Journal of magnetic resonance imaging : JMRI, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
38citing papers in PubMed, 4 pooled it
5.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

38 citing papers in PubMed, 4 syntheses or guidelines pooled it, 86 citations in OpenAlex.

  1. Guideline
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Quantifying abnormal alveolar microstructure in cystic fibrosis lung disease via hyperpolarizedJournal of cystic fibrosis : official journal of the European Cystic Fibrosis Society · 2024
    Article
  14. Article
  15. Article
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 6 institutions in 3 countries.

Jason C WoodsCenter for Pulmonary Imaging Research, Division of Pulmonary Medicine and Department of Radiology, Cincinnati Children's Hospital and University of Cincinnati, Cincinnati, Ohio, USA.ORCID 0000-0002-8080-7511
Jim M WildDepartment of Radiology, University of Sheffield, Sheffield, UK.
Mark O WielpützDepartment of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany.
John P ClancyCenter for Pulmonary Imaging Research, Division of Pulmonary Medicine and Department of Radiology, Cincinnati Children's Hospital and University of Cincinnati, Cincinnati, Ohio, USA.
Hiroto HatabuCenter for Pulmonary Functional Imaging, Department of Radiology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
Hans-Ulrich KauczorDepartment of Diagnostic and Interventional Radiology, University of Heidelberg, Heidelberg, Germany.
Edwin J R van BeekEdinburgh Imaging, Queen's Medical Research Institute, University of Edinburgh, Edinburgh, UK.ORCID 0000-0002-2777-5071
Talissa A AltesDepartment of Radiology, University of Missouri, Columbia, Missouri, USA.
Cincinnati Children's Hospital Medical Center · USHeidelberg University · DEBrigham and Women's Hospital · USThe Queen's Medical Research Institute · GBUniversity of Missouri · USUniversity of Sheffield · GB

Funding

UTE MRI to monitor CF lung disease and response to CFTR modulation in young childrenR01HL131012 · NHLBI · CINCINNATI CHILDRENS HOSP MED CTR · PI Raouf S. Amin, JASON C WOODS · 2016 to 2026
$6.8M
A Phase III Trial to Validate HP 129Xe MRI as a Functional Pulmonary Biomarker in Pediatric Lung DiseaseR44HL123299 · NHLBI · POLAREAN, INC. · PI EMAMI, KIARASH · 2017 to 2019
$3.0M
British Heart Foundation SP/14/6/31350Department of Health NIHR-RP-R3-12-027Medical Research Council MR/M008894/1NHLBI NIH HHS R01 HL131012NHLBI NIH HHS R44 HL123299
6 · The paper itself

Abstract

Pulmonary MRI can now provide high-resolution images that are sensitive to early disease and specific to inflammation in cystic fibrosis (CF) lung disease. With specificity and function limited via computed tomography (CT), there are significant advantages to MRI. Many of the modern MRI techniques can be performed throughout life, and can be employed to understand changes over time, in addition to quantification of treatment response. Proton density and T

Indexed as

Cystic FibrosisHumansLungMagnetic Resonance ImagingRespirationTomography, X-Ray Computedairwayscystic fibrosishyperpolarizedlongitudinallungmagnetic resonance imagingpulmonaryxenon

Identifiers

PMID31846139
PMCPMC7297663
OpenAlexW2995720869

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.